Therapy Areas: Oncology
Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe
24 August 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Monday that the European Commission has approved Trodelvy (sacituzumab govitecan-hziy) with Keytruda (pembroli...
GSK's Jemperli wins FDA priority review for advanced rectal cancer
24 August 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Monday that the US Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics L...
Anbogen Therapeutics enters collaborative research agreement with University of Tokyo for ABT-301 evaluation across multiple tumour types
24 August 2026 - Anbogen Therapeutics Inc (TPEx:7784), a Taiwan-based, clinical-stage precision oncology company, announced on Sunday that it has entered into a Collaborative Research Agreement (CRA) ...
Leads Biolabs NDA for Opamtistomig accepted by China's CDE
21 August 2026 - China-based biotechnology company Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) said on Friday that the Centre for Drug Evaluation of the National Medical Products Administration has ac...
Ipsen completes Kartos Therapeutics acquisition, strengthening late-stage oncology pipeline
21 August 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Friday that it has completed the acquisition of Kartos Therapeutics, adding the clinical-stage bio...
Nuvation Bio's safusidenib granted FDA Fast Track Designation for IDH1-mutant glioma treatment
21 August 2026 - Global oncology company Nuvation Bio Inc (NYSE:NUVB) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib, the compa...